Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06CZS
|
|||
| Former ID |
DCL001126
|
|||
| Drug Name |
V85546
|
|||
| Indication | Inflammation [ICD-11: 1A00-CA43.1] | Discontinued in Phase 1 | [1] | |
| Therapeutic Class |
Antiinflammatory Agents
|
|||
| Company |
Vernalis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Matrix metalloproteinase-12 (MMP-12) | Target Info | Inhibitor | [2] |
| NetPath Pathway | IL1 Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| WikiPathways | TGF beta Signaling Pathway | |||
| Degradation of collagen | ||||
| Matrix Metalloproteinases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020392) | |||
| REF 2 | Clinical pipeline report, company report or official report of Vernalis. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.